SWOG clinical trial number
S1204

A Sero-Epidemiologic Survey and Cost-effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients

Closed
Accrual
100%
Abbreviated Title
Viral Screening Study
Status Notes
This study closed to patient accrual 2/15/17.
Activated
08/29/2013
Closed
02/15/2017
Participants
NCORP, Medical Oncologists, Affiliates, SWOG

Research committees

Cancer Care Delivery
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Leukemia
Lung Cancer
Lymphoma
Melanoma
Myeloma

Eligibility Criteria Expand/Collapse

Patients must be presenting for evaluation or treatment of a new cancer malignancy (including hematologic). Confirmed diagnosis (obtained from patient's medical record) must be within 120 days prior to the first clinic visit. Patients must be registered within 90 days after their first clinic visit. Patients presenting for �second opinions� of confirmed malignancies are eligible, including those who have started cancer treatment at other facilities; Patients are allowed to participate in other clinical trials; must be at least 18 years of age; Patients must have had their blood drawn for viral status testing for HIV, HBV and HCV prior to registration or provide acceptable viral status documentation prior to registration; acceptable viral status documentation includes viral test results for any of all of the viruses, dated within 365 days prior to registration, or viral load documentation for any or all of the viruses, dated within 365 days prior to registration. Note that patients providing acceptable viral status documentation must have blood drawn for testing prior to registration for any of the three viruses not covered by the documentation. Patients must sign and give written informed consent in accordance with institutional and federal guidelines; Blood specimens for banking for future research is optional for sites and patients. Patient consent must be obtained before specimen is collected. Individuals are ineligible if they have been diagnosed with a malignancy other than the current malignancy within the past five years, with the exception of basal cell or squamous cell skin cancer, in situ cervical cancer, or in situ breast cancer. Individuals are eligible if they have had no evidence of disease for a prior malignancy except as noted above, for at least five years prior to randomization.

Publication Information Expand/Collapse

2019

The prevalence of HIV, Hepatitis B, and Hepatitis C among newly diagnosed cancer patients treated in academic and community oncology practices: SWOG S1204

S Ramsey;J Unger;L Baker;R Little;R Loomba;J Hwang;R Chugh;M Konerman;K Arnold;AR Menter;E Thomas;R Michels;C Walker Jorgensen;GV Burton;N Bhadkamkar;D Hershman JAMA Oncology Jan 17. doi: 10.1001/jamaoncol.2018.6437. [Epub ahead of print]

PMid: PMID30653226

2018

Prevalence of HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients Treated in Academic and Community Oncology Practices

S Ramsey;J Unger;L Baker;R Little;R Loomba;J Hwang;R Chugh;M Konerman;K Arnold;D Hershman J Clin Oncol 36, 2018 (suppl; abstr 6600); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session

2016

Stepwise development of a cancer care delivery research study to evaluate viral infections in cancer patients: SWOG S1204

JM Unger;DL Hershman;K Arnold;R Loomba;R Chugh;J Hwang;M O'Rourke;N Bhadkamkar;L Wang;A Siegel;TP Cooley;J Berenberg;BB Bridges;SD Ramsey Future Oncology, May;12(10):1219-1231; 2016 Mar 8 [Epub ahead of print]

PMid: PMID26952901 | PMC number: PMC4864045

Other Clinical Trials

SWOG Clinical Trial Number
SWOG-7436

Combined Modality Therapy of Breast Carcinoma Phase III

Research Committee(s)
Breast Cancer
Activated
01/09/1975
Closed
07/18/1979
Accrual
100%
Closed
Phase
III
Published
SWOG Clinical Trial Number
SWOG-7827

Combined Modality Therapy For Breast Carcinoma Phase III

Research Committee(s)
Breast Cancer
Activated
07/16/1979
Closed
08/01/1989
Accrual
100%
Closed
Phase
III
Published
SWOG Clinical Trial Number
SWOG-8312